

Jose Luis Calleja-Panero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3480219/publications.pdf>

Version: 2024-02-01

259
papers

13,634
citations

26630

56
h-index

22832

112
g-index

275
all docs

275
docs citations

275
times ranked

11066
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 406-414.e7.	4.4	23
2	Consenso AEEH «Consenso sobre métodos de detección y derivación de enfermedades hepáticas prevalentes ocultas». <i>Gastroenterología Y Hepatología</i> , 2023, 46, 236-247.	0.5	2
3	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Cut</i> , 2022, 71, 593-604.	12.1	62
4	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1343-1353.e16.	4.4	9
5	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318.	3.7	48
6	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
7	A cascade of care analysis on the elimination of hepatitis C from public hospitals in Madrid. <i>Communications Medicine</i> , 2022, 2, .	4.2	2
8	Editorial: clinical impact of sofosbuvir renal toxicity – more light on the way. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1052-1053.	3.7	1
9	Knowledge of liver fibrosis stage among adults with <scp>NAFLD</scp>/<scp>NASH</scp> improves adherence to lifestyle changes. <i>Liver International</i> , 2022, 42, 984-994.	3.9	24
10	Comparison of non-invasive fibrosis scores to predict increased liver stiffness in the general population with unknown liver disease: Searching for the primary physician's best friend. <i>Digestive and Liver Disease</i> , 2022, 54, 1209-1214.	0.9	3
11	Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 131-143.	3.7	9
12	Tacrolimus as an Effective and Durable Second-Line Treatment for Chronic Autoimmune Hepatitis: A Multicentric Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2826-2832.	2.3	6
13	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	2.0	28
14	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , 2021, 160, 193-205.e10.	1.3	97
15	Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1627-1633.	2.8	19
16	The Screening Guidelines for Hepatitis C Virus Infection as a milestone in the path towards hepatitis C virus elimination. <i>Revista Española De Enfermedades Digestivas</i> , 2021, 113, 156.	0.3	0
17	Mild ast elevation as an early sign of COVID-19 severity in a multicenter Madrid cohort. <i>Revista Española De Enfermedades Digestivas</i> , 2021, 113, 780-786.	0.3	2
18	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. <i>European Journal of Radiology</i> , 2021, 135, 109484.	2.6	20

#	ARTICLE	IF	CITATIONS
19	Hepatitis C reflex testing in Spain in 2019: A story of success. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2021, 39, 119-126.	0.3	0
20	Diagnóstico en un solo paso de la hepatitis C en 2019: una realidad en España. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2021, 39, 119-126.	0.5	15
21	Adding Branched-Chain Amino Acids to an Enhanced Standard-of-Care Treatment Improves Muscle Mass of Cirrhotic Patients With Sarcopenia: A Placebo-Controlled Trial. <i>American Journal of Gastroenterology</i> , 2021, 116, 2241-2249.	0.4	39
22	High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. <i>United European Gastroenterology Journal</i> , 2021, 9, 892-902.	3.8	12
23	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. <i>JHEP Reports</i> , 2021, 3, 100276.	4.9	5
24	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100290.	4.9	5
25	Non-malignant portal vein thrombosis in a cohort of cirrhotic patients: Incidence and risk factors. <i>Hepatology Research</i> , 2021, 51, 1064-1072.	3.4	5
26	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	3.7	28
27	Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 589-599.	3.7	36
28	Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1635-1642.	2.0	12
29	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. <i>JHEP Reports</i> , 2021, 3, 100368.	4.9	3
30	Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4885.	2.4	5
31	Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. <i>Scientific Reports</i> , 2021, 11, 24133.	3.3	13
32	Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	4.4	104
33	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	4.1	39
34	Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain. <i>Journal of Viral Hepatitis</i> , 2020, 27, 360-370.	2.0	39
35	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020, 73, 1368-1378.	3.7	158
36	Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis. <i>Clinical Infectious Diseases</i> , 2020, 71, 2726-2729.	5.8	23

#	ARTICLE	IF	CITATIONS
37	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 1037-1045.	3.7	69
38	Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19. <i>Journal of Infectious Diseases</i> , 2020, 222, 726-733.	4.0	43
39	Update on epidemiology of hepatitis B in a low-endemic European country: There is still much to do. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1261-1265.	2.0	6
40	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. <i>Journal of Hepatology</i> , 2020, 73, 1415-1424.	3.7	104
41	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020, 73, 17-25.	3.7	59
42	Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 332-347.	0.1	6
43	Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients. <i>Liver International</i> , 2020, 40, 2215-2227.	3.9	11
44	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 1088-1096.	3.7	75
45	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1140-1150.	3.7	97
46	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	3.7	112
47	Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 397-411.	0.3	7
48	Overall clinical and economic impact of non-alcoholic fatty liver disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 113, 396-403.	0.3	0
49	Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 6658-6668.	3.3	12
50	Preemptive TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , 2019, 69, 282-293.	7.3	144
51	Visceral fat is associated with cirrhotic portal vein thrombosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1017-1022.	3.0	7
52	FRI-225-Universal access to direct-acting antivirals treatment is not not enough to prevent late stage presentation of hepatitis C infection. <i>Journal of Hepatology</i> , 2019, 70, e493-e494.	3.7	5
53	FRI-439-Factor V and VIII may predict the risk of recurrent splanchnic thrombosis in patients with non-cirrhotic chronic portal vein thrombosis of local and idiopathic etiology not receiving anticoagulation. <i>Journal of Hepatology</i> , 2019, 70, e587.	3.7	1
54	FRI-197-Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, e477-e478.	3.7	0

#	ARTICLE	IF	CITATIONS
55	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> (English Edition), 2019, 42, 579-592.	0.1	2
56	SAT-424-Spleen transient elastography and suprahepatic vein dumping index can be useful to identify patients without acute and chronic response to beta-blockers. <i>Journal of Hepatology</i> , 2019, 70, e821.	3.7	1
57	PS-023-Factors predicting survival in patients with high-risk acute variceal bleeding treated with pre-emptive (Early)-TIPS. <i>Journal of Hepatology</i> , 2019, 70, e17-e18.	3.7	0
58	SAT-079-Respiratory infection in patients with cirrhosis and acute variceal bleeding on antibiotic prophylaxis: A multicenter observational study of 2138 patients. <i>Journal of Hepatology</i> , 2019, 70, e663-e664.	3.7	0
59	THU-124-Efficacy and safety of glecaprevir/pibrentasvir for the pangenotypic treatment of chronic hepatitis C in former intravenous drug users: Subanalysis from a Spanish real-world cohort (Hepa-C). <i>Journal of Hepatology</i> , 2019, 70, e213-e214.	3.7	0
60	FRI-496-Recurrence of hepatocellular carcinoma in patients with complete response treated with direct acting antivirals in clinical practice. <i>Journal of Hepatology</i> , 2019, 70, e617.	3.7	0
61	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019, 70, 874-884.	3.7	67
62	Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 267-271.	1.6	12
63	Impact of Sustained Viral Response in the Evolution of Minimal Hepatic Encephalopathy: a Prospective Pilot Study. <i>Annals of Hepatology</i> , 2019, 18, 203-208.	1.5	3
64	Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. <i>Journal of Hepatology</i> , 2019, 71, 666-672.	3.7	67
65	HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz214.	0.9	4
66	Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. <i>Journal of Hepatology</i> , 2019, 71, 660-665.	3.7	93
67	Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1127-1138.	2.0	10
68	SAT-096-Large spontaneous portosystemic shunt (SPSS) area is associated with hepatic encephalopathy and predicts mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e670.	3.7	0
69	Impact of sustained viral response in the evolution of minimal hepatic encephalopathy: A prospective pilot study. <i>Annals of Hepatology</i> , 2019, 18, 429-433.	1.5	3
70	PS-022-Optimal timing of endoscopy is associated with lower 42-day mortality in variceal bleeding. <i>Journal of Hepatology</i> , 2019, 70, e16-e17.	3.7	2
71	PS-200-The combination of HEPamet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD. <i>Journal of Hepatology</i> , 2019, 70, e133-e134.	3.7	3
72	Diagnosis of hepatitis C virus infection in Spain: An opportunity to improve. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> (English Ed), 2019, 37, 231-238.	0.3	0

#	ARTICLE	IF	CITATIONS
73	Î² blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2019, 393, 1597-1608.	13.7	375
74	Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with <scp>HCV GT4</scp> and compensated cirrhosis (<scp>AGATE Part II</scp>). <i>Health Science Reports</i> , 2019, 2, e92.	1.5	3
75	IDDF2019-ABS-0134...Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies. , 2019, , .		0
76	IDDF2019-ABS-0136...Sofosbuvir/velpatasvir for 12 weeks is safe and effective in patients undergoing dialysis. , 2019, , .		1
77	El diagnÃstico de la infecciÃ³n por el virus de la hepatitis C en EspaÃ±a: una oportunidad para mejorar. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2019, 37, 231-238.	0.5	19
78	OptimizaciÃ³n en el abordaje multidisciplinar del paciente con hepatitis C en la era de los antivirales de acciÃ³n directa. <i>GastroenterologÃa Y HepatologÃa</i> , 2019, 42, 8-13.	0.5	0
79	Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild/moderate fibrosis: Results from a real-world cohort. <i>Liver International</i> , 2019, 39, 90-97.	3.9	5
80	Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 527-535.e6.	4.4	19
81	Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2019, 37, 222-230.	0.5	16
82	Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic <scp>HCV</scp> infection: Results from the Spanish <scp>HEPA</scp> real-world cohort. <i>Journal of Viral Hepatitis</i> , 2019, 26, 55-64.	2.0	20
83	EliminaciÃ³n de la hepatitis C. Documento de posicionamiento de la AsociaciÃ³n EspaÃ±ola para el Estudio del HÃgado (AEEH). <i>GastroenterologÃa Y HepatologÃa</i> , 2019, 42, 579-592.	0.5	25
84	Definition of the profiles of hepatitis C virus patients based on the identification of risky practices in Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 731-737.	0.3	4
85	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 862-873.	0.3	12
86	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 154, 1694-1705.e4.	1.3	162
87	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018, 68, 1129-1136.	3.7	88
88	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>Journal of Hepatology</i> , 2018, 68, 940-948.	3.7	15
89	GuÃa de tratamiento de la infecciÃ³n por virus de la hepatitis C. AsociaciÃ³n EspaÃ±ola para el Estudio del HÃgado (AEEH). <i>GastroenterologÃa Y HepatologÃa</i> , 2018, 41, 597-608.	0.5	15
90	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). <i>GastroenterologÃa Y HepatologÃa (English Edition)</i> , 2018, 41, 597-608.	0.1	0

#	ARTICLE	IF	CITATIONS
91	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1260-1270.	3.7	70
92	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. <i>Gastroenterology</i> , 2018, 155, 1120-1127.e4.	1.3	76
93	Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. <i>American Journal of Gastroenterology</i> , 2018, 113, 1639-1648.	0.4	72
94	Probiotic supplementation with <i>Lactobacillus plantarum</i> and <i>Pediococcus acidilactici</i> for <i>Helicobacter pylori</i> therapy: A randomized, double-blind, placebo-controlled trial. <i>Helicobacter</i> , 2018, 23, e12529.	3.5	34
95	The efficiency of several one-step testing strategies for the diagnosis of hepatitis C. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 111, 10-16.	0.3	9
96	Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 784-793.	2.3	55
97	The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease. <i>BMC Infectious Diseases</i> , 2017, 17, 45.	2.9	17
98	Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 945-949.e1.	4.4	22
99	Eliminaci3n de la hepatitis C en Espa3a: adaptaci3n de un modelo matem3tico de salud p3blica partiendo del plan estrat3gico para el abordaje de la hepatitis C en el Sistema Nacional de Salud. <i>Medicina Cl3nica</i> , 2017, 148, 277-282.	0.6	24
100	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the HepaC registry. <i>Hepatology</i> , 2017, 65, 1810-1822.	7.3	78
101	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. <i>Journal of Hepatology</i> , 2017, 66, 1138-1148.	3.7	159
102	Successful Continuation of HCV Treatment After Liver Transplantation. <i>Transplantation</i> , 2017, 101, 1009-1012.	1.0	6
103	A pragmatic algorithm to rule out Non-alcoholic steatohepatitis in patients at risk of non-alcoholic fatty liver disease in spite of a normal ultrasound. <i>Journal of Hepatology</i> , 2017, 66, S160-S161.	3.7	1
104	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017, 37, 1823-1832.	3.9	10
105	Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 936-943.	2.0	48
106	Simeprevir in combination with sofosbuvir in treatment-naïve and experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 468-475.	3.7	30
107	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 1444-1453.	7.3	239
108	Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, 1400-1409.	0.4	26

#	ARTICLE	IF	CITATIONS
109	Preventing decompensation of cirrhosis with clinically significant portal hypertension and without high-risk varices: a new indication for non-selective beta-blockers (NSBB). <i>Journal of Hepatology</i> , 2017, 66, S97-S98.	3.7	4
110	Molecular characterization of Hepatitis C virus resistance-associated substitutions after interferon-free treatment failure by massive parallel sequencing. <i>Journal of Hepatology</i> , 2017, 66, S731.	3.7	0
111	Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System. <i>Medicina Clínica (English)</i> Tj ETQq1 1 0.784314 rgBT6/Overlo	3.7	0
112	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	8.1	208
113	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 791.	4.4	1
114	Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. <i>Journal of Viral Hepatitis</i> , 2017, 24, 823-831.	2.0	107
115	Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase <sc>II SATURN</sc> study. <i>Transplant Infectious Disease</i> , 2017, 19, e12696.	1.7	10
116	Validation of noninvasive methods to predict the presence of gastroesophageal varices in a cohort of patients with compensated advanced chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1867-1872.	2.8	54
117	Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2017, 66, 718-723.	3.7	90
118	Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2017, 24, 226-237.	2.0	22
119	Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. <i>Hepatology</i> , 2017, 65, 1293-1305.	7.3	225
120	Bacterial deoxyribonucleic is frequent in blood samples of patients with compensated cirrhosis and obesity and is associated with lack of decrease of portal pressure after an intensive lifestyle intervention. <i>Journal of Hepatology</i> , 2017, 66, S130.	3.7	0
121	Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. <i>Gastroenterology</i> , 2017, 153, 1273-1283.e1.	1.3	210
122	Treatment of patients with hepatitis C virus genotype 5 and 6: descriptive analysis of the Hepa-C registry. <i>Journal of Hepatology</i> , 2017, 66, S720.	3.7	1
123	Excellent efficacy but increased rate of severe adverse events in HCV-infected elderly patients undergoing interferon-free therapy. <i>Journal of Hepatology</i> , 2017, 66, S735.	3.7	0
124	Metabolic and biochemical phenotypes can distinguish different patterns of histological severity in biopsy-proven NAFLD. <i>Journal of Hepatology</i> , 2017, 66, S155-S156.	3.7	0
125	Portosystemic shunts in cirrhosis are associated to more complications and deteriorated quality of life: an international cohort study. <i>Journal of Hepatology</i> , 2017, 66, S386.	3.7	0
126	Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. <i>PLoS ONE</i> , 2017, 12, e0184550.	2.5	45

#	ARTICLE	IF	CITATIONS
127	Tenofovir <i>vs</i> lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. World Journal of Gastroenterology, 2017, 23, 7459-7469.	3.3	8
128	Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Taking Concomitant Proton Pump Inhibitors: 2017 Presidential Poster Award. American Journal of Gastroenterology, 2017, 112, S545-S546.	0.4	0
129	Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia. Technology and Health Care, 2016, 24, 111-120.	1.2	31
130	HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. PLoS ONE, 2016, 11, e0168544.	2.5	2
131	Development of hyperdynamic circulation and response to β -blockers in compensated cirrhosis with portal hypertension. Hepatology, 2016, 63, 197-206.	7.3	143
132	Treatment of Hepatitis C Virus in Patients with Advanced Cirrhosis: Always Justified? Analysis of the Hepa-C Registry. Journal of Hepatology, 2016, 64, S133.	3.7	8
133	Reactivation of Herpesvirus in Patients With Hepatitis C Treated With Direct-Acting Antiviral Agents. Clinical Gastroenterology and Hepatology, 2016, 14, 1662-1666.e1.	4.4	38
134	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. Journal of Hepatology, 2016, 65, 719-726.	3.7	883
135	Results of Radiofrequency Ablation in a Cohort of Cirrhotic Patients at Liver Transplantation. Journal of Hepatology, 2016, 64, S698.	3.7	0
136	Efficacy and Safety of HCV-Treatment with Direct-Acting Antiviral Agents Interferon-Free, in Patients with Severe Renal Impairment in Clinical Practice. Journal of Hepatology, 2016, 64, S779.	3.7	1
137	Endothelial Dysfunction, Macrophage Dysfunction and Emerging Cardiovascular Risk Factors in Patients with Hepatitis C Virus Infection Characterization and Potential Reversibility with Direct Acting Antiviral Agents. Journal of Hepatology, 2016, 64, S823.	3.7	1
138	Efficacy and Tolerability of Interferon-Free Antiviral Therapy in Kidney Transplant (KT) Recipients with Chronic Hepatitis C: Real-Life Data from the Spanish National Registry (HEPA-C). Journal of Hepatology, 2016, 64, S793-S794.	3.7	4
139	Safety and Efficacy of Sofosbuvir plus Simeprevir in a Spanish Cohort of 622 Cirrhotic Patients Infected with Genotypes 1 or 4. Journal of Hepatology, 2016, 64, S831.	3.7	2
140	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. Scientific Reports, 2016, 6, 31421.	3.3	33
141	Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting. Journal of Clinical Gastroenterology, 2016, 50, 779-789.	2.2	25
142	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology, 2016, 150, 1160-1170.e3.	1.3	232
143	Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. International Journal of Colorectal Disease, 2016, 31, 543-551.	2.2	106
144	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infectious Diseases, The, 2016, 16, 685-697.	9.1	402

#	ARTICLE	IF	CITATIONS
145	PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. <i>Journal of Hepatology</i> , 2016, 64, 800-806.	3.7	358
146	Arterioportal fistula, a rare cause of presinusoidal portal hypertension. <i>Gastroenterology y Hepatología</i> , 2016, 39, 43-45.	0.5	5
147	Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 62, 32-36.	5.8	92
148	Prevalence and outcome of portal thrombosis in a cohort of cirrhotic patients undergoing liver transplantation. <i>Revista Española De Enfermedades Digestivas</i> , 2016, 108, 716-720.	0.3	12
149	NS5A Resistance: Clinical Implications and Treatment Possibilities. <i>AIDS Reviews</i> , 2016, 18, 15-22.	1.0	4
150	Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015, 21, 5421.	3.3	7
151	Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study. <i>PLoS ONE</i> , 2015, 10, e0122613.	2.5	2
152	Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0138503.	2.5	3
153	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , 2015, 14, 477-486.	1.5	1
154	The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, 311-316.	3.7	12
155	LP13 : Effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. <i>Journal of Hepatology</i> , 2015, 62, S269-S270.	3.7	30
156	P0880 : Pharmacogenomic study to predict ribavirin and protease-inhibitor-related anemia in hepatitis C. <i>Journal of Hepatology</i> , 2015, 62, S671-S672.	3.7	0
157	A randomized trial to compare the efficacy and tolerability of sodium picosulfate-magnesium citrate solution vs. 4% polyethylene glycol solution as a bowel preparation for colonoscopy. <i>International Journal of Colorectal Disease</i> , 2015, 30, 1407-1416.	2.2	8
158	Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. <i>Journal of Clinical Virology</i> , 2015, 68, 56-60.	3.1	11
159	Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. <i>Journal of Hepatology</i> , 2015, 63, 564-572.	3.7	132
160	Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1846-1853.e1.	4.4	60
161	Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection. <i>Genes and Immunity</i> , 2015, 16, 297-300.	4.1	10
162	Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 46-54.	1.6	4

#	ARTICLE	IF	CITATIONS
163	Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. <i>Liver International</i> , 2015, 35, 90-100.	3.9	13
164	Undetectable <sc>HCV</sc>â€œ<sc>RNA</sc> at treatmentâ€œweek 8 results in highâ€œsustained virological response in <sc>HCV</sc> G1 treatmentâ€œexperienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015, 22, 469-480.	2.0	9
165	Idiopathic portal hypertension regarding thiopurine treatment in patients with inflammatory bowel disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 108, 79-83.	0.3	6
166	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , 2015, 14, 477-86.	1.5	0
167	P30: Entecavir has high efficacy and safety in Caucasian patients with chronic hepatitis B and coâ€œmorbidities. <i>Journal of Viral Hepatitis</i> , 2014, 21, 38-39.	2.0	0
168	Strategies to manage hepatitis <sc>C</sc> virus (<sc>HCV</sc>) disease burden. <i>Journal of Viral Hepatitis</i> , 2014, 21, 60-89.	2.0	161
169	P834 NON-INVASIVE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2014, 60, S349-S350.	3.7	0
170	Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study. <i>GastroenterologÃa Y HepatologÃa</i> , 2014, 37, 1-8.	0.5	2
171	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. <i>Journal of Viral Hepatitis</i> , 2014, 21, 34-59.	2.0	372
172	Historical epidemiology of hepatitis C virus (<sc>HCV</sc>) in selected countries. <i>Journal of Viral Hepatitis</i> , 2014, 21, 5-33.	2.0	211
173	Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under â€œReal-Lifeâ€œConditions. <i>Value in Health</i> , 2014, 17, A367.	0.3	0
174	Outcomes of peptic ulcer bleeding following treatment with proton pump inhibitors in routine clinical practice: 935 patients with high- or low-risk stigmata. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1181-1190.	1.5	10
175	P219 FINE MAPPING OF THE BUTYROPHILIN GENOMICS REGION: ROLE IN HEPATITIS C VIRUS INFECTION (HCV). <i>Journal of Hepatology</i> , 2014, 60, S139.	3.7	2
176	Reply to: â€œRenal impairment and anemia during triple therapyâ€œ. <i>Journal of Hepatology</i> , 2014, 60, 1100-1101.	3.7	1
177	P1041 TENOFOVIR MONOTHERAPY VERSUS LAMIVUDINE PLUS ADEFOVIR IN LAMIVUDINE-FAILURE PATIENTS RESCUED WITH LAMIVUDINE PLUS ADEFOVIR COMBINATION: INTERIM ANALYSIS OF THE TENOSIMP-B CLINICAL TRIAL. <i>Journal of Hepatology</i> , 2014, 60, S422.	3.7	1
178	P1132 PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION WITH PRIOR RELAPSE. <i>Journal of Hepatology</i> , 2014, 60, S458-S459.	3.7	2
179	O68 SOFOSBLUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY. <i>Journal of Hepatology</i> , 2014, 60, S28.	3.7	52
180	O167 ADDITION OF SIMVASTATIN TO STANDARD TREATMENT IMPROVES SURVIVAL AFTER VARICEAL BLEEDING IN PATIENTS WITH CIRRHOSIS. A DOUBLE-BLIND RANDOMIZED TRIAL (NCT01095185). <i>Journal of Hepatology</i> , 2014, 60, S525.	3.7	13

#	ARTICLE	IF	CITATIONS
181	P1058 LONG-TERM EFFICACY OF TENOFOVIR IN PREVIOUSLY TREATED AND NAIVE PATIENTS. RESULTS FROM THE SPANISH CHRONIC HEPATITIS B REGISTRY (CIBERHEP). <i>Journal of Hepatology</i> , 2014, 60, S429.	3.7	5
182	Severe splenic rupture after colorectal endoscopic submucosal dissection. <i>World Journal of Gastroenterology</i> , 2014, 20, 9618-9620.	3.3	8
183	Vascular hemichorea: case report and review. <i>Medwave</i> , 2014, 14, e5936-e5936.	0.5	1
184	Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations. <i>Journal of Hepatology</i> , 2013, 59, 1323-1330.	3.7	35
185	Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial. <i>Gastroenterology</i> , 2013, 145, 1035-1044.e5.	1.3	51
186	Impact of Treatment Failure on the Total Cost of Triple Therapy Including Boceprevir or Telaprevir Based on the French Early Access Program (ANRS CO20-CUPLIC) Study. <i>Value in Health</i> , 2013, 16, A350.	0.3	0
187	Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain. <i>Gastroenterology and Hepatology</i> , 2013, 36, 555-564.	0.5	1
188	210 SUSTAINED VIROLOGICAL RESPONSE WITH PEG-INTERFERON alfa-2a AND RIBAVIRIN DECREASES PORTAL PRESSURE GRADIENT AND PREVENTS CLINICAL DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C RELATED CIRRHOSIS. <i>Journal of Hepatology</i> , 2013, 58, S91.	3.7	0
189	894 IL28B-BASED MODEL FOR PREDICTION OF WEEK 4 VIRAL RESPONSE IN PEGINTERFERON-alfa2a + RIBAVIRIN TREATED HEPATITIS C GENOTYPE 1&4. FINAL REPORT WEEK 4 OPTIM STUDY. <i>Journal of Hepatology</i> , 2013, 58, S368.	3.7	0
190	Meta-analysis: pegylated interferon α 2a achieves higher early virological responses than α 2b in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 1065-1073.	3.7	6
191	Effect of proton pump inhibitors on the outcomes of peptic ulcer bleeding: comparison of event rates in routine clinical practice and a clinical trial. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 285-294.	1.5	6
192	Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30 Hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4727-4735.	3.2	22
193	Prevalence of viral hepatitis (B and C) serological markers in healthy working population. <i>Revista Espanola De Enfermedades Digestivas</i> , 2013, 105, 249-254.	0.3	23
194	Ethics and relations between industry and doctors. <i>Medwave</i> , 2013, 13, e5765-e5765.	0.5	0
195	Successful extracorporeal shockwave lithotripsy in chronic calcified pancreatitis management. <i>Revista Espanola De Enfermedades Digestivas</i> , 2013, 105, 566-567.	0.3	0
196	Gastric band cutter to remove a migrated gastric band. <i>Endoscopy</i> , 2012, 44, E40-E41.	1.8	3
197	908 FACTORS INVOLVED IN SUSTAINED VIRAL RESPONSE (SVR) ACHIEVEMENT IN PATIENTS WITH FAVORABLE IL28B CC GENOTYPE IN HEPATITIS C. <i>Journal of Hepatology</i> , 2012, 56, S353-S354.	3.7	0
198	923 INTERACTION BETWEEN RS12979860 POLYMORPHISM OF IL28B GENE WITH BASELINE PREDICTIVE FACTORS OF RESPONSE TO TREATMENT IN PATIENTS WITH HEPATITIS C. <i>Journal of Hepatology</i> , 2012, 56, S359-S360.	3.7	0

#	ARTICLE	IF	CITATIONS
199	Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1705-1710.	2.8	0
200	1109 HIGH VS STANDARD DOSE OF RIBAVIRIN PLUS PEGINTERFERON-ALFA-2A IN CHRONIC HEPATITIS C, GENOTYPE 3 AND HIGH VIRAL LOAD. FINAL RESULTS OF THE DARGEN-3 STUDY. <i>Journal of Hepatology</i> , 2012, 56, S437.	3.7	0
201	1154 PEGINTERFERON ALPHA-2A ACHIEVES HIGHER EARLY VIROLOGICAL RESPONSES (RVR AND CEVR) THAN PEGINTERFERON ALPHA-2B IN CHRONIC HEPATITIS C: META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS (RCT). <i>Journal of Hepatology</i> , 2012, 56, S456.	3.7	2
202	Quimioterapia en pacientes VHB positivos. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012, 104, 553-553.	0.3	0
203	PIN92 Patient Reported Outcomes Among Chronic Hepatitis C Patients Re-Treated with Peginterferon Alfa-2A/Ribavirin After Non-response to Peginterferon Alfa-2B/Ribavirin in Spain. <i>Value in Health</i> , 2011, 14, A282.	0.3	0
204	Boceprevir for Untreated Chronic HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2011, 364, 1195-1206.	27.0	2,352
205	Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2011, 54, 1114-1122.	3.7	105
206	A survey of chronic hepatitis B patient management practices in the European Union. <i>Journal of Viral Hepatitis</i> , 2010, 17, no-no.	2.0	7
207	260 SUCCESSFUL THERAPY WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN CAUSES A SUSTAINED DECREASE IN PORTAL PRESSURE IN PATIENTS WITH CHRONIC HEPATITIS C-RELATED CIRRHOSIS. <i>Journal of Hepatology</i> , 2010, 52, S109-S110.	3.7	1
208	1137 THE HLA CLASS I B*1801 ALLELE INFLUENCES HEPATOCELLULAR EXPRESSION OF AMOXICILLIN-CLAVULANATE LIVER DAMAGE AND OUTCOME IN SPANISH PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S439.	3.7	5
209	Hepatitis B reactivation and current clinical impact. <i>Revista Espanola De Enfermedades Digestivas</i> , 2010, 102, 542-52.	0.3	12
210	Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. <i>Hepatology</i> , 2009, 50, 1702-1708.	7.3	136
211	Double-guidewire technique for difficult bile duct cannulation: a multicenter randomized, controlled trial. <i>Gastrointestinal Endoscopy</i> , 2009, 70, 700-709.	1.0	125
212	Acquired chronic hepatocerebral degeneration due to cirrhosis from non-alcoholic steatohepatitis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2009, 101, 806-11.	0.3	2
213	Decrease in viral load at weeks 12 and 24 in patients with chronic hepatitis B treated with lamivudine or adefovir predicts virological response at week 48. <i>Revista Espanola De Enfermedades Digestivas</i> , 2009, 101, 763-7.	0.3	2
214	Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. <i>Antiviral Therapy</i> , 2009, 14, 23-32.	1.0	66
215	Infliximab in Ankylosing Spondylitis Associated With Chronic Hepatitis B Infection. Role of Lamivudine Therapy. <i>Reumatología Clínica (English Edition)</i> , 2008, 4, 159-161.	0.3	0
216	603 A SURVEY OF CHRONIC HEPATITIS B PATIENT MANAGEMENT PRACTICES IN EUROPE. <i>Journal of Hepatology</i> , 2008, 48, S225.	3.7	1

#	ARTICLE	IF	CITATIONS
217	1001 INTERIM ANALYSIS FROM TRIC-1 A STUDY OF METFORMIN WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAIVE GENOTYPE 1 CHRONIC HEPATITIS C WITH INSULIN RESISTANCE. <i>Journal of Hepatology</i> , 2008, 48, S375.	3.7	4
218	Portal Hypertensionâ€“Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1412-1417.	4.4	175
219	Portal vein filling: an unusual complication of needle-knife sphincterotomy. <i>Endoscopy</i> , 2007, 39, E245-E245.	1.8	15
220	[586] SAFETY, PHARMACOKINETICS AND ANTIVIRAL EFFECT OF BILB1941, A NOVEL HCV RNA POLYMERASE INHIBITOR, AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2007, 46, S222.	3.7	12
221	Impact of Nocturnal Heartburn on Quality of Life, Sleep, and Productivity: The SINERGE Study. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2858-2865.	2.3	18
222	485 The improved therapeutic effects of adefovir dipivoxil in patients with HBeAg-negative chronic hepatitis B offset against its increased cost compared to lamivudine. <i>Journal of Hepatology</i> , 2006, 44, S180.	3.7	1
223	Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 409-419.	3.7	19
224	<i>Helicobacter pylori</i> Infection in Patients with Erosive Esophagitis Is Associated with Rapid Heartburn Relief and Lack of Relapse After Treatment with Pantoprazole. <i>Digestive Diseases and Sciences</i> , 2005, 50, 432-439.	2.3	12
225	Selective Biliary Cannulation Using Pancreatic Guide-Wire Placement: Further Evidence Needed to Support the Use of an Already Known Technique. <i>Endoscopy</i> , 2004, 36, 457.	1.8	8
226	Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. <i>Gastroenterology</i> , 2004, 127, 1347-1355.	1.3	322
227	422 Efficacy and safety of adefovir for the treatment of patients with chronic hepatitis B (CHB) resistant to lamivudine in Spain. <i>Journal of Hepatology</i> , 2004, 40, 125.	3.7	0
228	Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. <i>Hepatology</i> , 2003, 37, 208-217.	7.3	381
229	Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: A double-blind RCT. <i>Hepatology</i> , 2003, 37, 1260-1266.	7.3	149
230	Autonomic neuropathy in end-stage cirrhotic patients and evolution after liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 1834-1835.	0.6	13
231	Liver transplantation for fulminant and subfulminant hepatic failure. <i>Transplantation Proceedings</i> , 2003, 35, 1855-1856.	0.6	7
232	Liver transplantation for autoimmune hepatitis: fulminant versus chronic hepatitis presentation. <i>Transplantation Proceedings</i> , 2003, 35, 1857-1858.	0.6	20
233	Autonomic neuropathy is associated with hemodynamic instability during human liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 1866-1868.	0.6	17
234	Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 837.	1.6	1

#	ARTICLE	IF	CITATIONS
235	Interferon, ribavirina y amantadina en pacientes con hepatitis C crónica (genotipo 1) sin respuesta al tratamiento previo con interferon y ribavirina. Gastroenterología Y Hepatología, 2003, 26, 465-468.	0.5	0
236	Selective intestinal decontamination (SID) ameliorates the immune and hemodynamic derangement of cirrhotic patients with high levels of lysozyme-binding protein (LBP). Journal of Hepatology, 2002, 36, 44.	3.7	1
237	Relationship between response to interferon-alpha and function of peripheral blood mononuclear cells in chronic hepatitis C patients. Digestive Diseases and Sciences, 2002, 47, 2154-2162.	2.3	3
238	Isosorbide Mononitrate in the Prevention of First Variceal Bleed in Patients Who Cannot Receive β -blockers. Gastroenterology, 2001, 121, 908-914.	1.3	103
239	Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive β -blockers. Gastroenterology, 2001, 121, 908-914.	1.3	94
240	Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts the type of response. Alimentary Pharmacology and Therapeutics, 2001, 15, 241-249.	3.7	3
241	Endoscopic Ultrasonography in The Diagnosis of Aorto-esophageal Fistula. American Journal of Gastroenterology, 2000, 95, 1374-1375.	0.4	1
242	Sustained response to interferon or to interferon plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Alimentary Pharmacology and Therapeutics, 1999, 13, 1179-1186.	3.7	75
243	Sclerotherapy in acute variceal bleeding. Gastrointestinal Endoscopy, 1999, 49, 140-141.	1.0	4
244	Hypersensitivity pneumonitis due to an ultrasonic humidifier. Allergy: European Journal of Allergy and Clinical Immunology, 1998, 53, 210-212.	5.7	32
245	Selective impairment of endothelium-mediated vasodilation in liver transplant recipients with cyclosporin A-induced hypertension. Hepatology, 1998, 27, 332-338.	7.3	12
246	Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology, 1998, 115, 116-123.	1.3	108
247	Helicobacter pylori eradication for the treatment of low-grade gastric MALT lymphoma: Follow-up together with sequential molecular studies. Annals of Oncology, 1997, 8, S37-S39.	1.2	38
248	Randomised trial of fibrin glue versus polidocanol for bleeding peptic ulcer. Lancet, The, 1997, 350, 1397-1398.	13.7	0
249	Accuracy of portal and forearm blood flow measurements in the assessment of the portal pressure response to propranolol. Journal of Hepatology, 1997, 27, 496-504.	3.7	30
250	Changes in gastrin and serum pepsinogens in monitoring of Helicobacter pylori response to therapy. Digestive Diseases and Sciences, 1997, 42, 1734-1740.	2.3	26
251	Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. Journal of Hepatology, 1996, 24, 308-312.	3.7	59
252	Favorable response to interferon but not to prednisone in chronic hepatitis C with non-organ specific antibodies. Gastroenterology, 1995, 108, A1043.	1.3	0

#	ARTICLE	IF	CITATIONS
253	Immunoproliferative small intestinal disease: An epidemiological, clinical and immunological analysis in 28 cases. <i>Gastroenterology</i> , 1995, 108, A277.	1.3	0
254	Hemodynamic effects of α_1 -adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. <i>Hepatology</i> , 1994, 20, 611-617.	7.3	64
255	Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. <i>Journal of Hepatology</i> , 1994, 21, 88-94.	3.7	75
256	Visceral leishmaniasis in patients infected with human immunodeficiency virus. <i>Journal of Infection</i> , 1990, 21, 261-270.	3.3	143
257	Primary liposarcoma of the lung in a young woman.. <i>Thorax</i> , 1990, 45, 298-299.	5.6	11
258	Localized lymphadenitis due to leishmania. Diagnosis by fine needle aspiration cytology.. <i>Postgraduate Medical Journal</i> , 1990, 66, 326-326.	1.8	8
259	Leishmaniasis masking tuberculosis. <i>Lancet, The</i> , 1990, 335, 299-300.	13.7	7